Search Results
89 results
Your search is now limited to «Clinical Trials» expert search.
GlobeNewswire 02/16/2019 06:00
In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release.
More from GlobeNewswire:
A Phase 2 trial of itacitinib in patients with ulcerative colitis has recently been initiated, as have Phase 2 trials of parsaclisib for the treatment of patients with pemphigus vulgaris, autoimmune hemolytic anemia and Sj¶gren’s syndrome.
More from Global Banking & Finance Review:
Immuno-Oncology News 02/12/2019 08:00
The open-label Phase 1 JAVELIN Solid Tumor trial (NCT01772004) was designed to study the safety and efficacy of Bavencio across multiple cancer types.
More from Immuno-Oncology News:
BioNewsFeeds 02/11/2019 12:57
Sanofi is conducting other three Phase 3 trials assessing isatuximab in combination with standard treatments for patients with multiple myeloma.
More from BioNewsFeeds:
The late-stage pipeline advanced significantly in 2018, with four compounds moving into Phase 3 clinical development.
More from Middle East North Africa Financial Network (MENAFN): 02/05/2019 09:18
Condition : Rheumatoid Arthritis Interventions : Drug: BAT1806; Drug: Actemra(EU-licensed) Sponsor : Bio-Thera Solutions Recruiting.
More from
Benzinga 02/04/2019 07:05
In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release.
More from Benzinga:
PR Newswire 02/04/2019 06:45
Increases to ≥5x and ≥10x upper limit of normal were observed for both ALT and AST in patients in Olumiant clinical trials.
More from PR Newswire:
Business Wire 01/22/2019 07:00
Aurinia will present the results of the clinical trial during a conference call and webcast presentation to be held at 8:00am ET Tuesday, January 22, 2019.
More from Business Wire: 01/19/2019 01:35
Janssen has initiated a proof-of-concept phase 2a clinical trial in patients with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease.
More from
Lancet 01/10/2019 19:12
The non-inferior efficacy and similar tolerability profile of dolutegravir plus lamivudine to a guideline-recommended three-drug regimen at 48 weeks in ART-naive adults supports its use as initial therapy for patients with HIV-1 infection.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications